- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01999088
Health Benefits of Functional Meat (With n-3 Fatty Acids and Rosemary Extract) on Low Risk for Cardiovascular Disease People
Randomized, Double-blind, Cross-over Placebo-controlled Study to Assess the Functional Meat Products With n-3 and Rosemary Extract Fluid in Biochemical Markers of Cardiovascular Disease Related Risk in Subjects at Low Risk for Cardiovascular Disease
Volunteers were randomly assigned by gender to follow of two 12 weeks experimental periods: intervention (I) and control (C) in different order (I/C or C/I). Both periods were separated by a 4 weeks wash-out interval during which subjects returned to their usual diet:
During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
Functional meat (FM) products (Functional cooked Ham (FH) and Functional cooked Turkey breast (FT)), were manufactured mixing the meats with the patented formula® (P200402755.2004). The amount of supercritical rosemary extract, deodorized salmon oil and vitamin E used was respectively, 0.02% w/w, 0.6% w/w, and 0.001% w/w.
Control meat (CM) products (Control cooked Ham (CH) and Control cooked Turkey (CT), were prepared without addition of the functional ingredients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Maadrid
-
Madrid, Maadrid, Spain, 28046
- Hospital Universitario La Paz
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women aged over 18 years
- At least 2 lipid profile parameters altered (TAG ≥150 mg /dl and/or total cholesterol ≥200 mg / dl and/or LDL ≥130 mg / dl and/or HDL ≥40mg/dl men or ≥ 50mg/dl women).
- Signed informed consent
Exclusion Criteria:
- Individuals with body mass index (BMI) ≥ 35 kg/m2
- Individuals with Diabetes Mellitus insulin dependent
- Individuals with disorders associated with eating behaviour
- Individuals with consumption of omega 3 functional foods, fish oil or antioxidant supplements
- Individuals inability to consume the test foods (ej. Vegetarians)
- Individuals with special diet due to disease as celiac disease, chronic renal failure, etc.
- Individuals with mental disease or low cognitive function.
- Individuals with consumption of drugs to weight lost.
- Individuals treated with drugs whose direct effect is on lipid profile (statins, fibrates, diuretics, corticosteroids or oral anti-inflammatory).
- Individuals with diseases that could be involucrate in weight lost (not controlled hypothyroidism, serious psychiatric illness, etc.).
- Pregnant women or lactating.
- Individuals with regular consumption of anti-inflammatory or glucocorticoids.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Functional meat
During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast).
It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
|
During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast).
It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
Other Names:
During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
Other Names:
|
|
Placebo Comparator: Control Meat
During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
|
During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast).
It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
Other Names:
During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lipid profile changes
Time Frame: 0, 12, 16 and 28 week
|
Parameters measured were: Cholesterol, LDL-Cholesterol, HDL-Cholesterol, Triglycerides, Apolipoprotein B and Apolipoprotein A.
|
0, 12, 16 and 28 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Framingham score changes
Time Frame: 0, 12, 16 and 28 week
|
Framingham score adapted to Spanish population (cardiovascular risk measurement)
|
0, 12, 16 and 28 week
|
|
Inflammatory markers changes
Time Frame: 0, 12, 16 and 28 week
|
Parameters measured were: Adiponectin, fibrinogen, TNFα, IL6, IL1B, PAI-1 and PCR
|
0, 12, 16 and 28 week
|
|
Oxidative Stress Parameters changes
Time Frame: 0, 12, 16 and 28 week
|
Parameters measured were: plasma antioxidant capacity (FRAP, ferric reducing antioxidant power), lipidic peroxidation (TBARS, thiobarbituric acid reactive substances assay), LDL-ox, .
8-iso-Prostaglandin F2α (8-iso-PGF2α), α-tocopherol and nitric oxide synthase (NOS).
|
0, 12, 16 and 28 week
|
|
Glucosa Metabolism changes
Time Frame: 0, 12, 16 and 28 week
|
Parameters measured were: glucose, basal insulin, HOMA index (glycemic insulin sensitivity index was calculated using the formula: HOMA-IR = fasting glucose (mmol/l)/fasting immunoreactive insulin (mU/ml)/22.5).
|
0, 12, 16 and 28 week
|
|
Blood pressure and heart rate changes
Time Frame: 0, 12, 16 and 28 week
|
0, 12, 16 and 28 week
|
|
|
Anthropometric parameters changes
Time Frame: 0, 12, 16 and 28 week
|
Parameters measured were: Weight, Height and waist circumference, tricipital skinfold thickness and fat mass percentage (FM%).
|
0, 12, 16 and 28 week
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Homocystein levels changes
Time Frame: 0, 12, 16 and 28 week
|
0, 12, 16 and 28 week
|
|
|
Sensory perception
Time Frame: 12, and 28 week
|
Subjects were asked to value taste and smell meats consumed, using a Visual Analogical Scale ranged 1-10 cm.
|
12, and 28 week
|
|
Adverse event
Time Frame: 12, and 28 week
|
Defined as any unfavourable, unintended effect reported by a subject or observed by the investigator during the study.
All were recorded along with the symptoms involved (nausea, vomiting, diarrhoea, halitosis, constipation).
|
12, and 28 week
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Carmen Gomez-Candela, MD, PhD, Hospital Universitario La Paz
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HULP-2889
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Risk for Cardiovascular Disease
-
GI View Ltd.Terminated
-
McGill UniversityCanadian Institutes of Health Research (CIHR)CompletedIncreased Risk for Cardiovascular DiseaseCanada
-
Memorial Sloan Kettering Cancer CenterCompletedHigh Risk for Postoperative Cardiovascular EventsUnited States
-
Centre Hospitalier Universitaire DijonTerminatedHigh Cardiovascular Risk Patients | Low Cardiovascular Risk PatientsFrance
-
Feng LiDuke University; Rutgers University; Tsinghua UniversityCompletedRisk Factors for Respiratory and Cardiovascular DiseaseChina
-
University of RochesterCompletedLow Risk (0-10% Chance) of Developing Cardiovascular Disease Within 10 Years Based on Risk Factors | Moderate Risk (10-20% Chance) of Developing Cardiovascular (Heart) Disease Within 10 Years Based on Risk FactorsUnited States
-
Stanford UniversityNot yet recruitingMCI With Increased Risk for Alzheimer Disease | Alzheimer s DiseaseUnited States
-
University of OxfordWellcome Trust; Jazz PharmaceuticalsNot yet recruitingClinical High Risk for Psychosis | Clinical High Risk for Psychosis (CHR) | Clinical High Risk for Developing PsychosisUnited Kingdom, Italy, Greece, Finland, Germany, Netherlands, Austria, Canada, Spain, Switzerland
-
Ostfold Hospital TrustUniversity of TromsoCompletedLow Risk Birth; Births With Low Risk FactorNorway
-
Jordan Collaborating Cardiology GroupThe Cardiovascular Academy Group of the JCS; The Jordan Cardiac Society (JCS); Istishari Hospital Department of Clinical ResearchTerminatedAtherosclerotic Cardiovascular Risk | Low-density-lipoprotein (LDL) CholesterolJordan
Clinical Trials on Functional Meet
-
University of PittsburghCambia Health FoundationCompleted
-
Josip Juraj Strossmayer University of OsijekRecruitingn-3 Polyunsaturated Fatty AcidsCroatia
-
University of California, San FranciscoNational Institute of Nursing Research (NINR); Soccer Without BordersEnrolling by invitationMental Health | Adolescent Health | Help-Seeking Behavior | Psychological Well BeingUnited States
-
Technical University of MunichUniversity of MelbourneCompletedFrontotemporal Dementia | Early Onset Alzheimer DiseaseGermany
-
Accelerate Diagnostics, Inc.Completed
-
University GhentKU LeuvenCompletedCerebral Palsy, SpasticBelgium
-
Riphah International UniversityCompletedCerebral PalsyPakistan
-
Mayo ClinicCompletedIndividuals With Functional Limitations Which May Impact Their Forward ReachUnited States
-
Assistance Publique - Hôpitaux de ParisHopital Universitaire Robert-Debre; Henri Mondor University Hospital; Fondation... and other collaboratorsCompleted
-
Spinal Stabilization TechnologiesTerminatedChronic Low-back Pain | Degenerative Disc DiseaseParaguay